You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Demand for SARS-CoV-2 testing sent lab revenues soaring while changes in patterns of patient care and regulations that could have impacts for years to come.
The organizations said they will move testing that is not time-sensitive from medical centers within Hackensack Meridian Health system to Quest laboratories.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
The company raised its revenue guidance to at least $9.35 billion based on higher than anticipated SARS-CoV-2 molecular testing volumes.
The EUA from FDA is the first for a diagnostic test for at-home, self-collection of patient samples for detecting the coronavirus and the flu.
Test capacity, particularly for rapid antigen testing, is set to explode in Q1 2021, but home and asymptomatic assays remain few and far between.
The FDA last week also reissued an EUA for a PCR-based SARS-CoV-2 test from Quest Diagnostics to permit its use with pooled samples.
News items for the in vitro diagnostics industry for the week of Nov. 23, 2020.
Quest will provide Montefiore with services including hospital lab management and esoteric testing and both hospitals with supply chain management.
News items for the in vitro diagnostics industry for the week of Nov. 16, 2020.